These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22948119)

  • 21. Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients.
    Sakurada T; Oishi D; Shibagaki Y; Yasuda T; Kimura K
    Hemodial Int; 2013 Oct; 17 Suppl 1():S2-6. PubMed ID: 24134326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.
    Toussaint ND; Lau KK; Polkinghorne KR; Kerr PG
    Nephrology (Carlton); 2011 Mar; 16(3):290-8. PubMed ID: 21342323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
    Guo H; Zhang X; Tang S; Zhang S
    Ren Fail; 2013; 35(10):1455-64. PubMed ID: 23992043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study.
    Ohtake T; Kobayashi S; Oka M; Furuya R; Iwagami M; Tsutsumi D; Mochida Y; Maesato K; Ishioka K; Moriya H; Hidaka S
    J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):439-46. PubMed ID: 23615577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
    Finn WF; Joy MS; Hladik G;
    Clin Nephrol; 2004 Sep; 62(3):193-201. PubMed ID: 15481851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients.
    Almirall J; Betancourt L; Esteve V; Valenzuela MP; López T; Ruiz A; Martínez-Ocaña JC; Calvet X
    Int Urol Nephrol; 2012 Feb; 44(1):231-6. PubMed ID: 21069570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
    Spasovski GB; Sikole A; Gelev S; Masin-Spasovska J; Freemont T; Webster I; Gill M; Jones C; De Broe ME; D'Haese PC
    Nephrol Dial Transplant; 2006 Aug; 21(8):2217-24. PubMed ID: 16595583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects.
    Pierce D; Hossack S; Robinson A; Zhang P; Martin P
    Clin Ther; 2012 Jun; 34(6):1290-1300.e2. PubMed ID: 22657252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
    Shigematsu T; Negi S;
    Nephrol Dial Transplant; 2012 Mar; 27(3):1050-4. PubMed ID: 21771755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
    Finn WF;
    Clin Nephrol; 2006 Mar; 65(3):191-202. PubMed ID: 16550750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice.
    Arenas MD; Rebollo P; Malek T; Moledous A; Gil MT; Alvarez-Ude F; Morales A; Cotilla E
    J Nephrol; 2010; 23(6):683-92. PubMed ID: 20540040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
    Hutchison AJ; Speake M; Al-Baaj F
    Nephrol Dial Transplant; 2004 Jul; 19(7):1902-6. PubMed ID: 15199195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of lanthanum carbonate versus calcium-based phosphate binders in dialysis patients: a meta-analysis.
    Zhai CJ; Yu XS; Sun QL; Li L; Zhang LT; Zhou AY; Wang R
    Clin Nephrol; 2014 Dec; 82(6):372-8. PubMed ID: 25295578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
    Ando R; Yama S; Ohnishi T; Iwamoto S; Kimura H; Chida Y; Ishida Y; Yamada K; Inagaki Y; Takayama M; Tachibana K; Kikuchi K; Inoue A; Ohtsuka M
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():2-8. PubMed ID: 24953759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
    Takeuchi K; Matsuda E; Sekino M; Hasegawa Y; Kamo Y; Kikuchi N; Sekino H
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():15-21. PubMed ID: 23586508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.